Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Synaptojanin-2-binding protein (SYNJ2BP) is a mitochondrial outer membrane protein with a PDZ domain, acting as a scaffold/adaptor involved in multiple cellular pathways. It regulates mitochondrial morphology, supports neuronal energy supply by controlling mitochondrial transport in motor neurons, and influences mitochondrial–ER contact sites. SYNJ2BP participates in endocytosis of activin type II receptors, modulates Notch signaling by stabilizing Notch ligands, and interacts with various membrane and cytoskeletal proteins. Reduction or dysfunction of SYNJ2BP is associated with enhanced tumor growth and invasiveness in hepatocellular carcinoma and increased susceptibility to neurodegenerative diseases such as ALS. SYNJ2BP is considered both a potential therapeutic target and disease biomarker in oncology and neurology[1][2][4][5][7][8].
Not targeted by approved drugs as of current knowledge; mechanisms include modulation of receptor stability, trafficking, and signal transduction pathways such as PI3K/AKT and MAPK (in cancer and neuronal cells)[2][5]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Synaptojanin-2-binding protein (SYNJ2BP).